BriaCell Therapeutics Corp. (BCTX): R&D Expense
$21.27M
Year ended 2025-07-31
$25.81M
Trailing 12 months to 2026-04-30
+38.4%
3-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-07-31 | $21.27M | -21.7% | 2025-10-16, From 2024-08-01 |
| 2024-07-31 | $27.18M | +77.2% | 2025-10-16, From 2023-08-01 |
| 2023-07-31 | $15.34M | +91.2% | 2024-10-29, From 2022-08-01 |
| 2022-07-31 | $8.02M | +296.9% | 2023-10-25, From 2021-08-01 |
| 2021-07-31 | $2.02M | n/a | 2022-10-28, From 2020-08-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| BriaCell Therapeutics Corp. (BCTX) | 2025-07-31 | $21.27M | -21.7% |
| Phio Pharmaceuticals Corp. (PHIO) | 2025-12-31 | $4.62M | +26.8% |
| Emmaus Life Sciences, Inc. (EMMA) | 2025-12-31 | $313.0K | -52.4% |
| Moleculin Biotech, Inc. (MBRX) | 2025-12-31 | $15.89M | -10.4% |
| Annovis Bio, Inc. (ANVS) | 2025-12-31 | $25.22M | +26.1% |
| Abvc Biopharma, Inc. (ABVC) | 2025-12-31 | $121.1K | -32.5% |
| Jyong Biotech Ltd. (MENS) | 2025-12-31 | $813.0K | -12.3% |
| Gain Therapeutics, Inc. (GANX) | 2025-12-31 | $10.21M | -5.4% |
| CervoMed Inc. (CRVO) | 2025-12-31 | $21.82M | +16.1% |
Compare BCTX, PHIO, EMMA, MBRX side by side · Screen every company in Pharmaceutical Preparations ↗